News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Michael Wang: Triple combination ABR was effective in treatment-naïve or relapsed/refractory MCL
Michael Wang/X
Mar 6, 2025, 08:51

Michael Wang: Triple combination ABR was effective in treatment-naïve or relapsed/refractory MCL

Michael Wang, Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center, shared an article by Tycel Phillips, et al. on X:

“Our Phase 1b study in Haematologica shows that the triple combination of acalabrutinib, bendamustine, and rituximab (ABR) was effective in patients with treatment-naïve or relapsed/refractory MCL, with a similar toxicity profile as single agents.”

Michael Wang: Triple combination ABR was effective in treatment-naïve or relapsed/refractory MCL

Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.

Authors: Tycel Phillips, et al.

Michael Wang: Triple combination ABR was effective in treatment-naïve or relapsed/refractory MCL

More posts featuring Michael Wang.

acalabrutinib bendamustine cancer fight against cancer Global fight against cancer Haematologica MD Anderson Cancer Center Michael Wang Myeloma OncoDaily Oncology Rituximab Tycel Phillips
Special Coverage
Blog
Mar 6, 2025, 08:52
Lisa Lacasse: Progress in Survival Thanks to Investments in Research
Science
Mar 6, 2025, 08:51
Michael Wang: Triple combination ABR was effective in treatment-naïve or relapsed/refractory MCL
Blog
Mar 6, 2025, 08:42
Health Stakeholders advocate for enhanced collaboration in EHDS Implementation - ECO
Blog
Mar 6, 2025, 08:34
Nominations for IASLC committees close soon - International Association for the Study of Lung Cancer
Blog
Mar 6, 2025, 08:24
Karen Knudsen: Closing a wonderful era for me in leading American Cancer Society
Science
Mar 6, 2025, 08:16
Armando Orlandi: Key predictors of response to chemotherapy-free regimens in HER2+/ER+ breast cancer
Blog
Mar 6, 2025, 08:15
Sakditad Saowapa: Excited to present my first oral abstract at JSMO25
Blog
Mar 6, 2025, 08:05
Guillermo Chantada: Martin Giusepponi joins Dina Mired's donation challenge for the pediatric cancer treatment
Blog
Mar 6, 2025, 08:03
The Future of Pediatric Liver Health is Here - ELPA
Blog
Mar 6, 2025, 07:51
Triparna Sen: Honored to deliver the Cancer Invasion and Metastasis Seminar at Johns Hopkins University
Science
Mar 6, 2025, 07:46
The 2024 State of Science Report from the EORTC Radiation Oncology Scientific Council - European Organisation for Research and Treatment of Cancer
Blog
Mar 6, 2025, 07:43
Chalothorn Wannaphut: Exciting Heme/Onc Match 2026 Webinar with Ben Ponvilawan